VIZZ sample distribution initiated nationwide to eye care professionals (ECPs) LENZ Therapeutics
(San Diego, CA) has announced that its product VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available in the US.
"We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States," said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. "Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia."
VIZZ contains aceclidine, which is differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect, and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY phase III clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes, lasting up to 10 hours. This level of near vision can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses.
"With VIZZ now available, we're giving people living with presbyopia a simple, fast-acting way to see up close again," said Shawn Olsson, Chief Commercial Officer of LENZ Therapeutics. "It's about restoring everyday confidence, including reading a phone, checking a price tag, or enjoying your active lifestyle glasses-free. We're excited to bring this new option to millions who want more freedom in their near vision."
Source: www.VIZZ.com
